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The circadian blood pressure (BP) rhythm is associated with
worsened cardiovascular outcomes in patients who have an
excessive morning BP surge and in those who lack the
normal nocturnal BP fall (non-dippers). There are multiple
pathophysiologic mechanisms underlying abnormalities in
circadian BP, most importantly abnormalities in sympathetic
nervous system activity, salt and volume balance, and
activation of the renin–angiotensin system. Several of these
factors can be modified by clinical interventions, either
related to lifestyle changes and/or antihypertensive drug
therapy. The timing of drug administration or specific drug
delivery systems that lead to a greater effect at night and/or
mitigate the early morning BP surge can correct abnormal
circadian rhythms. Although these strategies have not yet
been shown to alter clinical outcomes, it is reasonable to
understand their biologic basis and take them into
consideration when designing antihypertensive therapy.
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It has been known for over a century that systemic blood
pressure (BP) has a daily variation characterized by
substantial reductions during sleep. The circadian rhythm
of BP was ultimately established by Millar-Craig et al. using
continuous intra-arterial monitoring.1 This seminal study
showed that BP was highest mid-morning and then fell
progressively throughout the rest of the day; in addition, the
study showed that BP was lowest at night (nocturnal dip),
but rose before awakening (morning surge).1 These findings
highlighted the importance of the circadian rhythm of BP
with regard to the management of hypertension, a factor that
had been acknowledged since the mid-1960s.2
Subsequent to the descriptive findings related to BP
variability, investigators began to evaluate the physiological
characteristics that produce the BP rise during the early
morning and the substantial reductions in BP during sleep.
Although it became clear that the timing and amplitude of
the natural rhythm of BP is influenced by intrinsic factors,
such as neurohormonal regulation, the effects of the extrinsic
factors, such as physical activity and dietary sodium, are
probably of greater significance.3 Furthermore, behavioral
influences, such as mental activity and emotional state,4 and
lifestyle factors, such as smoking cigarettes and drinking
alcohol, can also affect the natural rhythm of BP.3
Growing evidence indicates that excessive BP levels during
the course of a circadian cycle may contribute to adverse
cardiac outcomes, especially when examining the relationship
between the morning peak in various cardiovascular (CV)
events with the post-awakening morning surge in BP. The
increased incidence of sudden death, non-fatal myocardial
infarction, unstable angina and stroke in the morning
indicates that a patient’s physiological status may play an
important role in the onset of CV events.5 Hence, there is a
need for 24-h control of BP to minimize this early morning
increase in CV risk.
CHARACTERISTICS OF THE CIRCADIAN FLUCTUATIONS
IN BP THAT MAY LEAD TO HARM
Early morning BP surge
In the early morning, BP rises sharply in response to the
natural activation of the sympathetic nervous system on
morning arousal.6–10 This early morning surge is also
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associated with other important hemodynamic and neuro-
hormonal changes, such as increase in heart rate, vascular
tone and blood viscosity, and decrease in vagal activity.6,11–13
The activity of the sympathetic nervous system appears to
be downregulated during the rapid eye movement period
of sleep, whereas awakening selectively stimulates the
sympathoadrenal branch of the sympathetic nervous system
and increases epinephrine levels.8 However, the increases in
BP and heart rate are controlled by direct sympathetic neural
input into the heart and vasculature in response to changes in
activity and posture, rather than by an endogenous surge of
plasma catecholamines.9
LOSS OF THE NOCTURNAL DECLINE IN BP (NON-DIPPERS)
The natural circadian rhythm of BP includes a nocturnal
decrease of 10–20% in BP. However, in 25–35% of
hypertensive patients a ‘non-dipper’ pattern occurs.
Non-dipping is arbitrarily defined as present when the
night time BP reduction is less than 10% compared to the
daytime pressure. This blunted nocturnal decrease occurs
when the natural rhythm of BP is disrupted (for a variety
of reasons), both in patients with essential hypertension and
with secondary forms of hypertension. Clinical investiga-
tions in patients with hypertension have associated a
blunted nocturnal BP decrease with increased adrenergic
and decreased vagal activity during sleep.14–16 In some
patients, there is even a significant nocturnal increase in BP
(‘reverse dippers’ or ‘risers’), a finding that is associated with
substantial cardiac morbidity.17 Less commonly, patients may
display a larger than usual (420%) decline in BP during
sleep compared with wakefulness; this profile of nocturnal
BP has been closely associated with increased white matter
ischemic lesions in the brain and an excessive morning BP
surge.18 At present, knowledge of the circadian profile of an
individual patient (through ambulatory BP monitoring) aids
in identifying increased risk. At this time, there are no data
that show that modifying an abnormal circadian rhythm
leads to improved outcomes.
CLINICAL IMPLICATIONS OF THE CIRCADIAN VARIABILITY
OF THE BP
As noted above, the early morning BP surge period is
associated with an increase in the incidence of CV events,
including stroke and myocardial infarction.19–21 Meta-
analyses indicate that there is a 40% higher relative risk
of acute myocardial infarction, a 29% increased risk of
sudden cardiac death, and a 49% higher relative risk of stroke
between 0600 h and 1200 h compared with the rest of
the day.20,21 This corresponds to approximately one in
every 11 myocardial infarctions, one in every 15 sudden
deaths, and one in every eight strokes being associated with
the ‘morning excess’.
The timing of onset of CV events strongly parallels the
circadian rhythm of BP; however, only limited data directly
link the two. In one of the more striking prospective analyses,
Kario et al. demonstrated a 2.7-fold increase in clinical stroke
risk in older patients with hypertension who were in the top
decile of the morning BP surge (455 mm Hg).22 After
adjustments for age, antihypertensive drug use, and 24-h BP
levels, each 10 mm Hg increase in the morning BP surge
conferred a 24% increase in stroke risk (P¼ 0.004). At this
time, no clinical trial has been devised to address the
relationship between a reduction in the early morning BP
and a possible reduction in CV events. Obstacles to doing
this sort of trial include the enormous sample size required
and the long period of follow-up that would be necessary.23
In the CONVINCE trial,23 it was estimated that in order to
show differences in early morning CV events with two
treatment strategies, more than 2000 events during
this period of time would be required – in order to support
this number of events, a patient population of 20 000
hypertensive patients would perhaps have to be followed
for nearly a decade.
Loss of the nocturnal decline in BP has been associated
with increased risk of cardiac, kidney, and vascular target
organ injury compared with patients whose decline in BP at
night is normal,24 and can be independent of the clinic
and 24-h mean BP values.25,26 Additionally, patients with
hypertension who exhibit a nocturnal BP increase compared
with daytime BP (risers) have the worst prognosis for
stroke and cardiac events.17,25 However, there is also some
evidence that patients with marked nocturnal BP declines
(extreme dippers) are at risk of lacunar strokes and silent
myocardial ischemia.18
Studies that have assessed the impact of elevated nocturnal
BP on the kidney have found similar results to those analyses
of cardiac and cerebrovascular target organ involvement
(see review by Thompson and Pickering for more
detailed information on ambulatory BP monitoring in
kidney disease26). Very early in the development of type 1
diabetes mellitus, Lurbe and co-workers showed that an
increase in night time systolic BP may have a key role in the
development of diabetic nephropathy.27 In contrast, patients
were less likely to progress from normalbuminuria to
microalbuminuria if their BP decreased during sleep. In a
retrospective cohort study of patients with a wide range of
renal function (average modification of diet in renal
disease glomerular filtration rate 81 ml/min/m2 in dippers,
76 ml/min/m2 in non-dippers), those who were non-dippers
had much faster loss of glomerular filtration rate over
an average follow-up of 3.2 years (11.7719.4 ml/min/year
versus 0.4713.5 for dippers, Po0.001).28 In a population
of patients with chronic kidney disease and hypertension
evaluated over 3 years, Timio et al. concluded that a
non-dipping pattern of ambulatory BP was associated with
a more rapid progression of renal insufficiency compared
with patients lacking nocturnal hypertension.29 In a similar,
larger study of 217 men with chronic kidney disease followed
over 3.5 years, Agarwal and Anderson found that one
standard deviation increase (11.8 mm Hg) in sleep systolic BP
increased the risk of death or dialysis by 26%.30 Hence, these
results have led to assumptions that high nocturnal BP and
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abnormal circadian BP could be a target for pharmacologic
interventions.
One important caveat in the interpretation of results from
studies analyzing the relevance of the dipping phenomenon is
the issue of its long-term reproducibility. Using the arbitrary
cutoff of 10% decline in BP, studies in different populations
have demonstrated reproducibility of dipping status on two
separate monitoring periods between 57 and 91%.31–34 In
essential hypertensives, target organ damage (left ventricular
hypertrophy, carotid intima thickness) is best predicted in
patients with a reproducible profile.31,35 Therefore, some of
the associations between non-dipping and adverse end points
may be weakened by the suboptimal reproducibility of the
nocturnal decline in BP.
EXTRINSIC FACTORS AFFECTING THE CIRCADIAN RHYTHM
OF BP
Effects of sleep quality and activity
Physical activity is the major determinant of BP rise during
the day.36,37 The influence of sleep and wakefulness on BP is
mediated through cyclic variations of the autonomic nervous
system.38,39 In the early morning, BP naturally rises sharply
in response to activation of the sympathetic nervous system
upon arousal.3,6,8 Sleep deprivation increases sympathetic
activity and may disrupt circadian rhythmicity.40,41
Dietary influences on the circadian variation of BP
The circadian BP rhythm, in particular the nocturnal
decline in BP, can be affected by sodium intake in patients
with hypertension.42,43 In fact, Uzu et al. showed that a
non-dipper nocturnal BP pattern can be converted to a
dipper pattern in response to salt restriction in salt-sensitive
patients with hypertension (Figure 1).44
Conversely, the morning surge in BP may be enhanced by
salt loading.43 Normotensive subjects may differ in electrolyte
handling and regulation during wakefulness, affecting the
circadian rhythm of BP.45,46 For example, following a period
of a high potassium diet, a proportion of normotensive
African-American adolescents switched from non-dipper
status to dipper status, with a reversal in night time BP
levels.46 Animal studies have shown that the circadian
pattern of expression of the sodium-hydrogen exchanger
(NHE3) was directly controlled by the biological clock
gene CLOCK:BMAL1 heterodimers, providing compelling
evidence that central biological clock regulation may be
directly involved in renal sodium handling.47
Ernst et al. compared the antihypertensive efficacy of
hydrochlorothiazide (HCTZ) and chlorthalidone on ambu-
latory BP in 30 patients with hypertension.48 The change
from baseline to week 8 in mean 24-h systolic ambulatory BP
indicated a greater reduction with chlorthalidone 25 mg/day
compared with HCTZ 50 mg/day. The greater reduction
appeared to be primarily because of its effect on reducing
night time mean systolic BP. The reduction in daytime mean
systolic BP was not significantly different between treatment
groups (Figure 2). Chlorthalidone has a much longer
elimination half-life than HCTZ, which could help sustain
a prolonged low level of diuresis, prevent the late period of
anti-diuresis (‘braking’), or have a more prominent and
prolonged vasodilatory effect producing a lower mean night
time BP.49
INTRINSIC FACTORS AFFECTING THE CIRCADIAN RHYTHM
OF BP
Autonomic and sympathetic nervous activity
Clinical studies of healthy subjects and patients with spinal
injuries50,51 support a direct role for the autonomic nervous
system in the regulation of the circadian variability of BP. In
these studies, BP increased independently of activity in
neurologically intact patients with lower spinal cord injuries,
but not in patients with sympathetic decentralization or
higher spinal cord injuries.50 This sympathetic neural activity
may contribute to the regulation of BP over the 24-h period.
Additionally, higher resting measurements of sympathetic
nerve activity were associated with greater daytime BP
variability and a more marked nocturnal decline in BP in
healthy normotensive subjects.51 However, some investigators
suggest that the existence of the non-dipper phenomenon
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Figure 1 | Sodium restriction shifts the circadian rhythm of BP
from non-dipper to dipper in sodium-sensitive hypertension.
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may not result from disruption of sympathetic neural
activity, but from a corresponding decrease in parasympa-
thetic function.52
Renin–angiotensin–aldosterone system
The renin–angiotensin–aldosterone system (RAAS), mainly
via production of angiotensin II, is a key regulator of BP. The
RAAS is activated in the early morning before arousal as a
result of sympathetic neuronal activation.53,54 In addition,
both renin and aldosterone demonstrate significant circadian
patterns in both normotensive and hypertensive indivi-
duals,54 with peak values detected early morning then falling
to their lowest point in late evening (Figure 3). A similar
pattern has been observed for angiotensin II.53
‘UTILIZATION’ OF THE PATHOPHYSIOLOGY OF THE
CIRCADIAN VARIABILITY OF BP FOR THE TREATMENT
OF HYPERTENSION
The available evidence reported above demonstrates two
distinct findings. First, the early morning surge in hyperten-
sion, clearly associated with increases in stroke events in older
patients with hypertension, is mediated in part by the
sympathetic nervous system and through the RAAS. Second,
the pathophysiology leading to a loss of decline in nocturnal
BP is probably mediated RAAS activation and volume excess.
Therefore, these findings allow us to examine the potential
for blockade of the systems leading to these abnormal profiles
in circadian BP. On a more pragmatic level, the pharmaco-
dynamics of antihypertensive drugs must play a role in these
considerations, as control of nocturnal BP and BP during the
early morning period will require that agents either have a
reasonably long half-life or be administered twice daily.
Modification of the timing of drug administration can
alter the circadian BP profile. In fact, modification of the
time of drug administration for many of the antihypertensive
agents may affect the extent of 24-h BP control and modify
the circadian rhythm, including the conversion from a non-
dipper to dipper profile.55,56 These effects are most uniform
with blockers of the RAAS, which typically will have a
substantial effect on nocturnal BP when administered at
night whereas also maintaining adequate control during the
daytime (Table 1).56
Drugs with long duration of action may be particularly
useful to this purpose. White et al. evaluated the effects of
telmisartan alone and in combination with HCTZ on 24-h
BP, including the early morning period.57 Patients with
hypertension received telmisartan 40 mg/day; if BP remained
uncontrolled after 2 weeks, the dose was increased to 80 mg/
day; if BP was still uncontrolled after a further 4 weeks,
HCTZ 12.5 mg was added and continued for a final 4-week
period. Twenty-four hour ambulatory BP monitoring was
performed at baseline and the end of the treatment period in
1628 patients. Telmisartan alone and in combination
with HCTZ produced significant reductions in both
daytime and night time mean BP. The effects of telmisartan
were sustained over the entire dosing period, reflective of its
long duration of action.
As most analyses have shown that renin activity begins to
rise during the night and peaks in the morning period,
another pharmacologic approach to consider in the treat-
ment of nocturnal and early morning hypertension would
be a long-acting direct renin inhibitor. Stanton et al. have
provided data supporting the notion that aliskiren, a direct
renin inhibitor with a plasma half-life of approximately
40 h might provide efficacy in patients with abnormal
circadian BP variability, particularly in the high-risk popula-
tions discussed herein.58 In addition, Mitchell et al. reported
an analysis of ambulatory BP monitoring in 216 patients with
hypertension who were randomized to 8 weeks’ treatment
with aliskiren 150, 300, or 600 mg once daily or placebo
(Abstract: Mitchell J, Oh B, Herron J, Chung J, Khan M,
Satlin A. Once-daily aliskiren provides effective, smooth 24-h
BP control in patients with hypertension. J Clin Hypertens
2006; 8 (Suppl A): P-209). Aliskiren significantly reduced
mean 24-h ambulatory BP compared with placebo at all
dosages. Consistent with its long half-life, effective BP
lowering was maintained throughout the 24-h dosing period,2.0
PR
A 
(ng
/m
l/h
)
PA
 (n
g/d
l)
PA
 (n
g/d
l)
1.5
1.0
0.5
0.0
20
15
10
5
0
20
15
10
5
0
Time of day (h)
08:00 08:0012:00 16:00 20:00 24:00 04:00
2.0
PR
A 
(ng
/m
l/h
)
1.5
1.0
0.5
0.0
Time of day (h)
08:00 08:0012:00 16:00 20:00 24:00 04:00
Time of day (h)
08:00 08:0012:00 16:00 20:00 24:00 04:00
Time of day (h)
08:00 08:0012:00 16:00 20:00 24:00 04:00
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aldosterone concentration in normotensive and hypertensive
subjects (n¼ 10 per group). Reproduced from Portaluppi et al.54
PA¼plasma aldosterone; PRA¼plasma renin activity.
Table 1 | Nocturnal blood pressure is reduced to a greater
extent with evening (2200) versus morning (0800) dosing of
quinapril 20 mg, without loss of daytime efficacy
Quinapril 20 mg once daily
Placebo
run-in
Morning
dosing (0800)
Evening
dosing (2200)
Daytime SBP (mm Hg) 154716 138716 137714
Daytime DBP (mm Hg) 10177 8979 9079
Night time SBP (mm Hg) 140715 132720 127718**
Night time DBP (mm Hg) 9077 83710 8179*
Heart rate (beats/min) 7379 71710 7278
DBP, diastolic blood pressure; SBP, systolic blood pressure.
Data from Palatini et al.56
*Po0.05, **Po0.01 versus morning administration.
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persisting overnight and throughout the high-risk period in
the early hours of the morning.
Of note is that, despite the potential benefits of conversion
of a non-dipping pattern to a dipping pattern, there does
remain the possibility that excessive BP reduction at night
might be associated with orthostatic hypotension or excessive
hypotension during sleep in certain individuals, particularly
the elderly. Thus, in the ideal situation, changes in drug
administration time should be followed by repeat ambulatory
BP monitoring to assess the effects of therapy and rule out an
excessive BP fall during the night.59 A limitation to this
approach, however, is the limited coverage provided by some
of the third-party payers for ambulatory BP monitoring (in
the United States).
In perspective, it is important to recognize the importance
of adequate BP control over the entire 24-h period,
particularly the early morning hours. Several of the
pathophysiological systems responsible for the circadian BP
variability, especially salt balance and the RAAS, can be
modulated by appropriate, long-acting therapy, and such
interventions may result in improved clinical outcomes. The
confirmation that correcting abnormal circadian rhythms
results in clinical benefit will require clinical trials that
specifically test this hypothesis, such as studies wherein
patients are randomized to different drug-dosing schedules
with efficacy confirmed by sequential ambulatory BP
monitoring, and relevant outcomes assessed. These outcomes
could be initially comprised of surrogate measures, such as
changes in left ventricular mass, carotid intima-media
thickness, ischemic cerebral lesions, or proteinuria. If safety
is ascertained and probable benefit is suggested, larger
studies with conventional CV or renal end points would
then be justified.
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